Kestra Medical Technologies (KMTS) CEO reports 29,822 tax-cover sales

Rhea-AI Filing Summary

Kestra Medical Technologies president and CEO Brian Daniel Webster reported sales of 29,822 common shares of KMTS in three transactions on July 30, July 31 and August 3, 2026. The shares were sold at weighted average prices between $22.0577 and $24.1100 solely to cover tax withholding obligations from the vesting and settlement of restricted stock units.

Insider Trade Summary

Net Seller: 29,822 shares

Net Sell 3 txns

Insider Webster Brian Daniel

Role See Remarks

Sold 29,822 shs ($692K)

Type	Security	Shares	Price	Value
Sale	Common Shares F1, F4	13,017	$23.9244	$311K
Sale	Common Shares F1, F3	8,948	$22.6039	$202K
Sale	Common Shares F1, F2	7,857	$22.7225	$179K

Holdings After Transaction: Common Shares — 527,115 shares (Direct)

Footnotes (4)

1. F1. The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.
2. F2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.2524 to $23.1700. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
3. F3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.0577 to $22.9200. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
4. F4. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.6400 to $24.1100. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Key Figures

Total shares sold: 29,822 shares July 30, 2026 sale volume: 7,857 shares July 30, 2026 price range: $22.2524–$23.1700 +4 more

7 metrics

Total shares sold 29,822 shares Aggregate common shares sold across the three reported transactions

July 30, 2026 sale volume 7,857 shares Common shares sold on 2026-07-30 at a weighted average price

July 30, 2026 price range $22.2524–$23.1700 Weighted average sale price range for 7,857 shares sold on 2026-07-30

July 31, 2026 sale volume 8,948 shares Common shares sold on 2026-07-31 at a weighted average price of $22.6039

July 31, 2026 price range $22.0577–$22.9200 Weighted average sale price range for 8,948 shares sold on 2026-07-31

August 3, 2026 sale volume 13,017 shares Common shares sold on 2026-08-03 at a weighted average price of $23.9244

August 3, 2026 price range $23.6400–$24.1100 Weighted average sale price range for 13,017 shares sold on 2026-08-03

Key Terms

sell to cover transactions, weighted average price, restricted stock units, tax withholding obligations

4 terms

sell to cover transactions financial

"required to be sold by the reporting person pursuant to sell to cover transactions"

weighted average price financial

"The price in Column 4 is a weighted average price. The prices at which"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

restricted stock units financial

"tax withholding obligations in connection with the vesting and settlement of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"nondiscretionary sale of shares required to be sold ... to satisfy tax withholding obligations"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/03/2026 - 07:27 PM Accepted by SEC EDGAR 08/03/2026 - 07:26 PM Learn about SEC filing dates

FAQ

What insider activity did Kestra Medical (KMTS) report in this Form 4?

Kestra Medical reported that CEO Brian Daniel Webster sold 29,822 common shares in three transactions. Footnotes state these were nondiscretionary sell-to-cover sales to satisfy tax withholding on vesting and settlement of restricted stock units.

Over what dates did the KMTS CEO sell the 29,822 shares and at what prices?

The CEO’s 29,822-share tax-related sales occurred on July 30, July 31 and August 3, 2026. Weighted average sale prices ranged from $22.0577 to $24.1100, with detailed price ranges for each day disclosed in the footnotes.

Were the KMTS CEO’s reported share sales discretionary or tax-related?

According to the footnotes, the reported sales were nondiscretionary sell-to-cover transactions. They were required to be sold to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units, rather than discretionary portfolio sales.

How many KMTS shares did the CEO sell in each individual transaction?

Brian Daniel Webster sold 7,857 shares on July 30, 8,948 shares on July 31 and 13,017 shares on August 3, 2026. Each transaction involved Kestra Medical common shares held directly by the reporting person.

What does “weighted average price” mean in the KMTS CEO’s Form 4 footnotes?

The footnotes explain that the reported prices are weighted average prices. Actual sale prices for each transaction date ranged over specified intervals, and the reporting person offers to provide the exact number of shares sold at each price within those ranges upon request.

Were the KMTS CEO’s sales made under a Rule 10b5-1 trading plan?

The document-level Rule 10b5-1 checkbox is not marked as a plan. Instead, footnote F1 characterizes the sales as nondiscretionary sell-to-cover transactions executed to satisfy tax withholding obligations from restricted stock unit vesting and settlement.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Webster Brian Daniel

(Last) (First) (Middle)

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WASHINGTON 98033

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	07/30/2026		S(1)		7,857	D	$22.7225(2)	549,080	D
Common Shares	07/31/2026		S(1)		8,948	D	$22.6039(3)	540,132	D
Common Shares	08/03/2026		S(1)		13,017	D	$23.9244(4)	527,115	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.

2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.2524 to $23.1700. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.0577 to $22.9200. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

4. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.6400 to $24.1100. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Remarks:

President and Chief Executive Officer

	/s/ Brian Daniel Webster	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)